医疗专业人员

下面列出了当前开展的临床试验。

根据地点、状态和其他条件对此研究列表进行过滤。

1. A Study To Evaluate Oncologic Outcomes And Quality Of Life In Sinonasal Cancer Patients

   Rochester, Minn.

   This is a multi-site study with several other leading centers studying sinonasal cancers. The purpose of this study is to gain a better understanding of the treatment and significant morbidity associated with sinonasal cancer and identify the impact this disease has on quality of life. In addition, several additional endpoints will focus on survival and optimal treatment strategies. Additional components will also included genomic and molecular analysis of tumor tissue as we search for novel targets for therapy.

    

    

2. Phase 1 Trial Of ST-001 NanoFenretinide In Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

   Scottsdale/Phoenix, Ariz.

   This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

3. Actinium Therapy For Late-stage Aggressive Sarcomas

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The goal of this clinical trial is to learn about the safety of drug [Ac225]RTX-2358 and the diagnostic imaging agent [Cu64]LNTH-1363S. Additionally Ratio Therapeutics will learn if [Ac225]RTX-2358 drug is effective in treating advanced sarcoma.

   The main questions the study aims to answer in Phase/Part 1 of the trial are:

   • Is [Ac225]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients.

   • What is the most tolerable dose of [Ac225]RTX-2358

   • Does the treatment show effectiveness on advanced sarcoma

   Participants will:

   • Take drug [Ac225]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months

   • Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests.

   • For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests

   • Remain in long term follow-up for a period of four additional years

4. A Study To Explore Tumor Biology In Metastatic Esophageal And Gastric Cancer Patients

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to explore various biomarkers in the post-treatment tissue of patients who have responded to cancer therapy and compare it to the biopsy performed prior to cancer treatment.

5. 3D Ultrasound Imaging For Breast Cancer Diagnosis

   Rochester, Minn.

   The purpose of this study is to evaluate the effectiveess of a new 3D ultrasound imaging technology combining B-mode, microvessel imaging, shear wave elastography, and machine learning for breast lesion diagnosis.

6. Global Trial In APG2575 For Patients With CLL/​SLL

   Jacksonville, Fla.

   The purpose of this study is to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

7. A Study Of Clonal Hematopoiesis (CH) And Hematological Toxicity After Cancer Treatment

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The overall objective of this project is to combine robust clinical data (e.g. prior chemotherapy or radiation exposure, cumulative radiotheranostic dose) with geneticclonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in radiotheranostic treated solid tumor patients.

8. Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)

   Jacksonville, Fla.

   UP-NEXT is a double-blind, randomized, placebo controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion for patients once every four weeks. Patients with recurrent, platinum-sensitive high-grade serous ovarian cancer (HGSOC) including fallopian tube and primary peritoneal cancer expressing high levels of NaPi2b.

9. Melanoma In-transit Tissue Bank And Molecular Analysis For Personalized Therapies

   Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to establish a tissue bank to collect patient tissue for genomic analysis, allowing identification of genomic signatures that predict response and failure to the individual therapy.  Once this is complete treatment will be directed based on the genomic signature of patients individual tumor.

    

    

10. Testing The Addition Of MEDI4736 (Durvalumab) To Chemotherapy Before Surgery For Patients With High-Grade Upper Urinary Tract Cancer

    Rochester, Minn., Jacksonville, Fla.

    The purpose of this study is to compare the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.